OncoMed Enrolls First Patient in Phase 1b Anti-RSPO3 Trial
11 janv. 2016 08h30 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Jan. 11, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics,...
OncoMed Announces Publication of Anti-RSPO Antibody Research in Cancer Research
08 janv. 2016 08h30 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Jan. 08, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology...
OncoMed Pharmaceuticals Appoints Perry Karsen to Board of Directors
06 janv. 2016 08h30 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Jan. 06, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc., (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology...
OncoMed Achieves $72.5 Million in Milestone Payments From Celgene; Announces Year-End Cash Balance
05 janv. 2016 08h30 HE
|
OncoMed Pharmaceuticals, Inc.
$70 Million Safety and $2.5 Million Clinical Candidate Designation Milestones Achieved Enters 2016 with $227 Million in Pro-Forma Cash REDWOOD CITY, Calif., Jan. 05, 2016 (GLOBE NEWSWIRE) --...
OncoMed Pharmaceuticals CEO to Present at the 34th Annual JPMorgan Healthcare Conference
04 janv. 2016 08h30 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Jan. 04, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cell (CSC) and...
OncoMed Presents Vantictumab Biomarker Data at the San Antonio Breast Cancer Symposium (SABCS)
11 déc. 2015 08h30 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Dec. 11, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) presented new data related to the development of a novel predictive biomarker for vantictumab...
OncoMed Pharmaceuticals to Present at Upcoming Investor Conferences
12 nov. 2015 17h42 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Nov. 12, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cell (CSC) and...
OncoMed Presents Data From Brontictuzumab, Vantictumab and Anti-DLL4/VEGF Bispecific Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
09 nov. 2015 08h30 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Nov. 09, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) presented clinical and preclinical data related to three of its clinical-stage programs at the...
OncoMed Presents Immuno-Oncology Data for Combined Blockade of DLL4, VEGF and PD1 at the Society for Immunotherapy of Cancer Annual Meeting
07 nov. 2015 12h45 HE
|
OncoMed Pharmaceuticals, Inc.
NATIONAL HARBOR, Md. and REDWOOD CITY, Calif., Nov. 07, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and...
OncoMed Pharmaceuticals Reports Third Quarter 2015 Financial Results
05 nov. 2015 07h00 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Nov. 05, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel cancer stem cell (CSC) and immuno-oncology...